Nimotuzumab in Children With HGG
Phase-II-Study of Efficacy of OSAG 101 (Theraloc®) for Adolscent Patients With Recurrent High Grade Glioma
Sponsor: CRM Biometrics GmbH
This observational or N/A phase trial investigates High Grade Glioma and is currently completed. CRM Biometrics GmbH leads this study, which shows 8 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Dec 2020 — Jan 2021 [monthly]
Completed
-
Sep 2020 — Dec 2020 [monthly]
Completed
▶ Show 3 earlier versions
-
Jun 2018 — Sep 2020 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Completed NA
First recorded
Jun 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CRM Biometrics GmbH
- Children's Medical Hospital, Medical School Hannover, Hannover, Germany
- Children's Medical Hospital, University of Bonn, Germany
- Children's Medical Hospital, University of Essen, Essen, Germany
- Children's Medical Hospital, University of Homburg/Saar, Homburg/Saar, Germany
- Dept. of Neuropediatrics and Muscle Disorders, University of Freiburg, Germany
- Dept. of Statistics, University of Dortmund, Germany
- Dr. von Haunersches Children's Medical Hospital, University of Munich, Germany
- Heinrich-Heine University, Duesseldorf
- Oncoscience AG
- University Hospital Augsburg
- University of Bonn
- University of Cologne
- University of Regensburg
- University of Wuerzburg
- Universitätsklinikum Hamburg-Eppendorf
For direct contact, visit the study record on ClinicalTrials.gov .